Hallmarks of liver cancer: Therapeutic implications.

Back in 2000, scientists developed a framework called the hallmarks of cancer to understand the complex ways normal cells transform into tumors. A recent scientific review looks at how this blueprint has completely changed the way we treat primary liver cancer, a disease known for its high mortality rates. Primary liver cancer is mostly made up of two types: hepatocellular carcinoma, or HCC, which accounts for about 85 percent of cases, and intrahepatic cholangiocarcinoma, or iCCA, making up roughly 10 percent.

The review breaks down how each type of liver cancer operates using these hallmarks. For example, HCC thrives by keeping its growth signals permanently switched on, building its own blood supply, and hiding from the body's natural defenses. By understanding that this cancer evades the immune system, doctors have been able to use immunotherapies to significantly improve patient survival over the last two decades.

Conversely, iCCA relies on a slightly different set of survival skills, like rewiring its cellular metabolism alongside continuous growth and immune evasion. The exciting news for iCCA is that roughly 45 percent of these cases are driven by actionable genetic mutations, such as changes in the FGFR2, IDH1, ERBB2, or BRAF genes. Because these alterations act like specific targets, doctors can use precision oncology to attack the cancer directly. It is worth noting that this paper is a review of existing literature, meaning it synthesizes current knowledge rather than presenting new clinical trial data.